<DOC>
	<DOCNO>NCT01800734</DOCNO>
	<brief_summary>Physiology study perform patient type 1 diabetes define standardize mixed meal test : 1 . The relationship fast insulin analogue administration i.v . infusion subcutaneous pump plasma insulin concentration tissue insulin action ; 2 . The relationship insulin action , glucose flux glucose concentration , latter one measure plasma estimate s.c. glucose-sensor ; 3 . The concentration curve potential modifier glucose-insulin system ( i.e . : glucagon , incretin hormone , free fatty amino acid ) . On basis data , silico phenocopies patient ( virtual patient ) create measure glucose control coefficient , quantify role played component glucose-insulin system glucose concentration . One final purpose research develop optimize algorithm able integrate continuous glucose monitoring continuous subcutaneous fast insulin analogue infusion , know closed-loop control ( CLC ) artificial pancreas .</brief_summary>
	<brief_title>Mixed Meal Test Type 1 Diabetes : Optimization Artificial Pancreas-Pilot Study</brief_title>
	<detailed_description>The maintenance close-to-normal blood glucose level slow onset progression long-term microvascular , possibly macrovascular , complication patient type 1 diabetes . Artificial pancreas integrate CLC [ CLC algorithm take account continuous glucose monitoring ( CGM ) read effect previous insulin infusion continuously compute amount insulin dose administer ] aim minimize , real time , glucose variability prevent extreme glucose excursion ( hypoglycemia hyperglycemia ) . Despite important development sensor pump technology , artificial pancreas system must cope anatomical functional barrier one encounter normally function glucose-insulin system physiology . For instance , CGM device measure glucose concentration interstitium , blood compartment , introduce time lag due glucose diffusion plasma interstitial fluid . Furthermore , insulin ( actually , one current fast insulin analogue ) deliver subcutaneous adipose tissue , blood , directly access systemic , portal circulation . Owing hindrance , develop smart suitable CLC algorithm still ongoing process . This research aim alleviate shortcoming carry clinical physiology study aim improve development optimization suitable control algorithm . Twenty adults patient type 1 diabetes , regularly attend Division Endocrinology Metabolic Diseases University Verona School Medicine , use continuous subcutaneous fast insulin analogue infusion ( CSII ) permanent pump subcutaneous glucose sense enrol . Inclusion criterion ( see detail ) diagnosis type 1 diabetes define WHO least 12 month confirm C-peptide negative . Exclusion criterion recurrent severe hypoglycemia unawareness clinically significant nephropathy , neuropathy , proliferative retinopathy . Standard clinical parameter assess patient . Metabolic test carry Division Endocrinology Metabolic Diseases University Verona School , start 08:00 a.m. two separate day random order 10-12-h overnight fast . Two metabolic test perform : euglycemic insulin clamp standardize mixed meal test . A. Euglycemic insulin clamp . A standard euglycemic insulin clamp carry assess insulin sensitivity , previously describe ( 1 ) . Subjects instruct use usual nocturnal fast insulin analogue basal rate , leave unchanged least five hour begin test . A CGM device insert two day test calibrate capillary blood glucose ( measure glucometer ) pre-established hour day . Human insulin concentration raise i.v . prime ( 0.8 U/m^2 BSA ) maintain constant i.v . infusion ( 40 mU/min·m^2 BSA ) . Plasma glucose allow fall reach physiologic range ( i.e . &lt; 5.6 mmol/L ) , clamp 5.0 mmol/L least 60 min appropriately change intravenous infusion 20 % dextrose . Glucose measure bedside YSI Glucose Analyzer . Blood sample collect timed interval measure plasma insulin ( fast analogue human insulin ) , free fatty acid , glucagon . Continuous glucose ( interstitial glucose ) monitoring perform throughout insulin clamp . B . Mixed meal test . This test perform assess pathophysiology glucose control standardize physiologic challenge . Subjects Indian corn free cane sugar free diet least one week study instruct use usual nocturnal fast insulin analogue basal rate , leave unchanged least five hour begin test . A CGM device place properly work throughout test . All participant ingest standardize mixed meal ( 292 Kcal , 38,9 g carbohydrate , 8,9 g fat 14 g protein ) , form maize polenta plus seasoned Italian parmesan cheese , monitor 300 minute thereafter . Right meal ingestion , s.c. fast insulin analogue bolus administer pump , accord individual insulin-to-carbohydrate ratio correction dose . The 13C/12C ratio maze starch different carbohydrate source allow detection polenta-derived glucose circulation . Plasma glucose , free fatty acid , amino acid , insulin , glucagon , incretin hormone concentration assess baseline entire test . The plasma 13C/12C glucose ratio throughout test monitor isotope ratio mass spectrometry . CGM data collect . This test determine time course plasma glucose , 13C/12C glucose ratio ( hence , meal-derived endogenous glucose ) , insulin , free fatty acid , aminoacids , glucagon , incretin hormone mixed meal . In study , blood sample put ice quickly spun 1500 g +4°C . Plasma/serum collect stored -80°C . Both test ( insulin clamp mixed meal ) form biological biobank study . The combined analysis insulin clamp mixed meal test data allow build comprehensive model glucose insulin system mixed meal test subject , thereby result silico virtual patient , accord well establish methodology develop laboratory . The collection virtual patient type 1 diabetes undergo mixed meal test form silico biobank derive form study . Virtual patient use carry Metabolic Control Analysis ( MCA ) , i.e . compute glucose control coefficient ( CCs ) , quantify role play component ( e.g . : absorption rate fast insulin analogue , carbohydrate absorption gut , etc . ) system determine glucose concentration time point mixed meal patient type 1 diabetes , close parallelism analysis previously carry u patient type 2 diabetes undergo intravenous glucose tolerance test ( 2 ) . Furthermore , incretin hormone , glucagon substrate response mixed meal quantify , allow putative identification modifier glucose-insulin system ( one : glucagon ) . This database instrumental devise control algorithm able guarantee normal glucose regulation mixed meal patient type 1 diabetes CGM insulin pump therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>patient must age 18 ( inclusive ) 65 year old ; patient must diagnose type 1 diabetes ( positive islet cell antibody ; use insulin pump treat his/her diabetes least 1 year ; actively use carbohydrate/insulin ratio insulin bolus adjustment order keep blood glucose predefined range ; patient HbA1c 6,0 % 9,0 % ( standardized DCCT ) ; patient must willing avoid consumption acetaminophen contain product study involve DexCom ( one CGM system employ study ) use ; patient must demonstrate proper mental status cognition study ; patient sign informed consent prior study entry . diabetic ketoacidosis within 6 month prior enrollment ; severe hypoglycemia result seizure loss consciousness 12 month prior enrollment ; pregnancy breast feeding ; uncontrolled microvascular ( diabetic ) complication ( diabetic nonproliferative retinopathy ) history laser coagulation , proliferative diabetic retinopathy , know diabetic nephropathy ( microalbuminuria normal creatinine ) neuropathy require treatment ; uncontrolled arterial hypertension ( diastolic blood pressure &gt; 90 mmHg and/or systolic blood pressure &gt; 160 mmHg ) ; condition may increase risk hypoglycemia uncontrolled coronary artery disease previous year ( e.g . history myocardial infarction , acute coronary syndrome , therapeutic coronary intervention , coronary bypass stenting procedure , stable unstable angina , episode chest pain cardiac etiology document EKG change , positive stress test catheterization coronary blockage &gt; 50 % ) , congestive heart failure , history cerebrovascular event , seizure disorder , syncope , adrenal insufficiency , neurologic disease atrial fibrillation ; drug affect glucose metabolism ( oral steroid , thiazide diuretic , betablockers , betaagonist , nicotinic acid , immunosuppressant agent , antiretroviral drug antipsychotic ) ; impair hepatic function measure alanine aminotransferase aspartate aminotransferase &gt; three time upper reference limit ; impaired renal function measure creatinine &gt; 1.2 time upper limit normal ; anticoagulant therapy aspirin ; know current recent alcohol drug abuse ; psychiatric disorder would interfere study task ( e.g . inpatient psychiatric treatment within 6 month prior enrollment ) ; mental incapacity , unwillingness language barrier preclude adequate understanding cooperation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Mixed meal test</keyword>
	<keyword>Insulin pump</keyword>
	<keyword>Continuous glucose monitoring</keyword>
	<keyword>Metabolic control analysis</keyword>
	<keyword>Closed loop control</keyword>
	<keyword>Artificial pancreas</keyword>
</DOC>